Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Disease, Chronic Obstructive

Explore clinical trials studying Pulmonary Disease, Chronic Obstructive. Study availability and eligibility vary by location and protocol.

4,003 public trials 391 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Disease, Chronic Obstructive trial results

Completed

Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01285492

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +6 more
Locations
  • Novartis Investigative Site Anjo, Aichi-ken, Japan
  • Novartis Investigative Site Nagoya, Aichi-ken, Japan
  • Novartis Investigative Site Nishio, Aichi-ken, Japan
  • Novartis Investigative Site Akita, Japan
View all 35 locations
View Trial Details
Completed

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

NCT01072396

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 205.440.1006 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 205.440.1015 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
  • 205.440.1002 Boehringer Ingelheim Investigational Site Torrance, California, United States
  • 205.440.1018 Boehringer Ingelheim Investigational Site Hartford, Connecticut, United States
View all 15 locations
View Trial Details
Completed

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

NCT00530842

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 205.334.4309 Boehringer Ingelheim Investigational Site Gänserndorf, Austria
  • 205.334.4308 Boehringer Ingelheim Investigational Site Hallein, Austria
  • 205.334.4306 Boehringer Ingelheim Investigational Site Leoben, Austria
  • 205.334.4301 Boehringer Ingelheim Investigational Site Linz, Austria
View all 42 locations
View Trial Details
Completed

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

NCT00563381

Conditions
Chronic Disease, Disease Attributes, Lung Diseases, +5 more
Locations
  • 205.389.1020 Boehringer Ingelheim Investigational Site Feldbach, Austria
  • 205.389.1010 Boehringer Ingelheim Investigational Site Feldkirch, Austria
  • 205.389.1003 Boehringer Ingelheim Investigational Site Gänserndorf, Austria
  • 205.389.1011 Boehringer Ingelheim Investigational Site Grimmenstein/Hochegg, Austria
View all 752 locations
View Trial Details
Completed

Tiotropium In Exercise

NCT00525512

Conditions
Behavior, Chronic Disease, Disease Attributes, +8 more
Locations
  • 205.368.01023 Boehringer Ingelheim Investigational Site Jasper, Alabama, United States
  • 205.368.01022 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • 205.368.01003 Boehringer Ingelheim Investigational Site Los Angeles, California, United States
  • 205.368.01008 Boehringer Ingelheim Investigational Site Fort Collins, Colorado, United States
View all 62 locations
View Trial Details
Completed

The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01490125

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease, Disease Attributes, +10 more
Locations
  • Novartis Investigative Site Brussels, Belgium
  • Novartis Investigative Site Gilly, Belgium
  • Novartis Investigative Site Jambes, Belgium
  • Novartis Investigative Site Jette, Belgium
View all 43 locations
View Trial Details
Completed

A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)

NCT01021891

Conditions
Chronic Disease, Chronic Obstructive Pulmonary Disease (COPD), Disease Attributes, +6 more
Locations
  • Diabetes & Glandular Disease Research Assoc PA San Antonio, Texas, United States
  • Medical University Graz Graz, Austria
  • University Medical Centre Groningen Zuidlaren, Netherlands
  • Medicines Evaluation Unit (MEU) Manchester, England, United Kingdom
View Trial Details

Related conditions